Resumen
Aunque se ha descrito una alta probabilidad de control de pacientes recientemente diagnosticados con medicamentos de primera clase, se ha mostrado también como esta probabilidad se reduce al requerir tratamientos adjuntos de segunda línea. Por esta razón el descubrimiento y entendimiento de nuevos mecanismos farmacocinéticos y farmacodinámicos se ha convertido en uno de los puntos de mayor relevancia al diagnosticar y tratar pacientes con epilepsia. Estos argumentos han permitido desarrollar nuevos medicamentos que aumentan las opciones de tratamiento en pacientes epilépticos. Aunque estas opciones muestran resultados prometedores, la evidencia que los soporta se basa en la mayoría de los casos en estudios fase III de aprobación, por tal razón se hace necesario el diseño de nuevas pruebas que soporten su eficacia y seguridad en escenarios clínicos más próximos a la realidad. Presentamos una revisión no sistemática que discute los principales aspectos de estos medicamentos.
Citas
Matagne A, Margineanu DG, Kenda B et al. Anticonvulsive and anti-epileptic properties of bribaracetam (UCB 34714), a high affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol 2008; 154: 1662-1671.
Von Rosenstiel P. Brivaracetam (UCB 34714). Neurotherapeutics 2007; 4: 84-87.
Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol 2008; 66: 71-75.
Sargentini-Maier ML, Espie P, Coquette A, Stockis A. Pharmacokinetics and metabolism of C-brivaracetam a novel SV2A ligand in healthy subjects. Drugs Metab Dispos 2008; 36: 36-45 .
www.clinicaltrials.gov.
Deshpande LS, Nagarkatti N, Sombati S, DeLorenzo RJ. The novel antiepileptic drug carisbamate (RWJ 333369) is effective in inhibiting spontaneous recurrent seizure discharge and blocking sustained repetitive firing in cultured hippocampal neurons. Epilepsy Res 2008; 79: 158-165. (46)
Francois J, Boeher A, Nehlig A. Effects of carisbamate (RWJ 333369) in two models of genetically determined generalized epilepsy, THE GAERS and the audiogenic Wistar AS. Epilepsia 2008; 49: 393-399.
Novak GP, Kelley M, Zannikos P, Kelin B. Carisbamate (RWJ 333369). Neurotherapeutics 2007; 4: 106-109.
Mannens GS, Hendricks J, Janssen CG et al. The absortion, metabolism and excretion of the novel neuromodulator RWJ 333369 in humans. Drug Metab Dispos 2007; 35: 554-565.
Yao C, Doose DR, Novak G, Bialer M. Pharmacokinetics of the new antiepileptic and CNS drug RWJ 333369 following single and multiple dosing in humans. Epilepsia 2006; 47: 1822-1829.
Chien S, Yao C, Mertens A et al. An interaction study between the new antiepileptic and CNS drug carisbamate (RWJ 333369) and lamotrigina and valproic acid. Epilepsia 2007; 48: 1328-1338.
Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 2006; 3: 273-294.
Sperling MR, Greenspan A, Cramer JA et al. Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo trials. Epilepsia 2009; 3: 333-343.
Cady RK, Mathew N, Diener HC et al. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial. Headache 2009; 2: 216-226.
Errington AC, Coyne L, Stohr T et al. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 2006; 50: 1016-1019.
Errington AC, Stohr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selective enhances slow inactivation of voltage gated-sodium channels. Mol Pharmacol 2008; 73: 157-169.
Ben-Menachem E, Biton V, Jatuzis D et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial onset seizures. Epilepsia 2007, 48: 1308-1317.
Bialer M, Johannssen SI, Kupferberg HJ et al. Progress report on new antiepileptic drugs: a summary of the Eight Eliat Conference (EILAT VIII). Epilepsy Res 2007; 73: 1-52.
Chung S, Sperling MR, Biton V et al. Lacosamide as adjunctive therapy for partial onset seizures: A randomized controlled trial. Epilepsia 2010. [Epub ahead of print].
Harris JA, Murphy JA. Lacosamide: an adjunctive agent for partial onset seizures and potential therapy for neuropathic pain. Ann Pharmacother 2009; 11: 1809-1817.
Rauck RL, Shaibani A, Biton V et al. Lacosamide in painful diabetic neuropathy: a phase 2 double blind placebo controlled study. Clin J Pain 2007; 2: 150-158.
Berry D, Millington C. Analysis of pregabalin at therapeutic concentrations in human plasma/serum by reversed phase HPLC. Ther Drug Monit 2005; 27: 451-456.
Arroyo S. Rufinamide. Neurotherapeutics 2007; 4: 155-162.
Deeks ED, Scott LJ. Rufinamide. CNS Drugs 2006; 56: 814-819.
Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: Clinical pharmacokinetics and concentration response relantionship in patients with epilepsy. Epilepsia 2008; 49: 1123-1141.
Wheless JW, Conry J, Krauss G, Mann A, LoPresti A, Narurkar M. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies. J Child Neurol 2009; 12: 1520-1525.
Wheless JW, Vásquez B. Rufinamide a novel broad-spectrum antiepileptic drug. Epilepsy Curr 2010; 1: 1-6.
Elger CE, Stephan H, Mann A et al. A 24-week multicenter, randomized, double blind, parallel group,
Acta Neurol Colomb Vol. 26 No. 1 Suplemento (1:1) Marzo 2010
dose-ranging study of rufinamide in adults and adolescent with inadequately controlled partial epilepsy. Epilepsy Res 2010; 2-3: 255-263.
Kluger G, Glauser T, Krauss G et al. Adjunctive rufinamide in Lennox-Gastaut Syndrome; a long-term open label extension study. Acta Neurol Scand 2010. [Epub ahead of print].
Howes JF, Bell C. Talampanel. Neurotherapeutics 2007; 4: 126-129.
French JA. Vigabatrin. Epilepsia 1999; (Supl. 5): S11-S16.
Willmore LJ, Abelson MB, Ben-Menachem et al. Epilepsia 2009; 2: 163-173.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.